Wang Zetao, Liao Youguo, Wang Canlong, Tang Chenqi, Fang Cailian, Luo Junchao, Liu Hengzhi, Mo Xianan, Wang Zicheng, Shen Lingfang, Wang Junjuan, Chen Xiao, Yin Zi, Li Jianyou, Shen Weiliang
Department of Orthopedics, Huzhou Central Hospital, Affiliated Huzhou Hospital, Zhejiang University School of Medicine, Huzhou, China.
Department of Orthopedic Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.
J Orthop Translat. 2023 Aug 23;42:73-81. doi: 10.1016/j.jot.2023.07.006. eCollection 2023 Sep.
Rotator cuff tendinopathy is a common musculoskeletal disorder that imposes significant health and economic burden. Stem cell therapy has brought hope for tendon healing in patients with final stage rotator cuff tendinopathy. Some clinical trials have confirmed the effectiveness of stem cell therapy for rotator cuff tendinopathy, but its application has not been promoted and approved. There are still many issues that should be solved prior to using stem cell therapy in clinical applications. The optimal source and dose of stem cells for rotator cuff tendinopathy should be determined. We also proposed novel prospective approaches that can overcome cell population heterogeneity and standardize patient types for stem cell applications.
This review explores the optimal sources of stem cells for rotator cuff tendinopathy and the principles for selecting stem cell dosages. Key strategies are provided for stem cell population standardization and recipient selection.
肩袖肌腱病是一种常见的肌肉骨骼疾病，会带来重大的健康和经济负担。干细胞疗法为终末期肩袖肌腱病患者的肌腱愈合带来了希望。一些临床试验已证实干细胞疗法对肩袖肌腱病有效，但其应用尚未得到推广和批准。在临床应用干细胞疗法之前，仍有许多问题需要解决。应确定用于肩袖肌腱病的干细胞的最佳来源和剂量。我们还提出了新的前瞻性方法，可克服细胞群体异质性并规范干细胞应用的患者类型。
本综述探讨了用于肩袖肌腱病的干细胞的最佳来源以及选择干细胞剂量的原则。为干细胞群体标准化和受体选择提供了关键策略。
